Liuhe Ningyuan Entrepreneurship Board IPO "Terminated" Withdrawn" as a provider of CRO and CDMO services focusing on the field of small molecule drug chemistry synthesis.

On January 14th, Beijing's Luhe Ningyuan Pharmaceutical Technology Co., Ltd. (referred to as Luhe Ningyuan) had its IPO approval status on the ChiNext board of the Shenzhen Stock Exchange changed to "terminated (withdrawn)". Due to Luhe Ningyuan and the sponsor withdrawing their application for listing, the Shenzhen Stock Exchange decided to terminate the IPO review process according to the Shenzhen Stock Exchange Stock Issuance and Listing Review Rules (2024 revised edition) Article 62. The prospectus shows that Luhe Ningyuan is a professional CRO/CDMO service provider in the field of small molecule drug chemistry synthesis, focusing on the core aspects of new drug research and development. The company emphasizes chemical synthesis services as its foundation, focusing on research and innovation in chemical synthesis methods and processes, and has built a one-stop service platform for small molecule new drug research and development chemistry synthesis, providing services covering all stages of small molecule new drug research and development for global pharmaceutical companies, innovative drug companies, and CDMO/CMO companies. The main businesses of the company include: small molecule drug chemical synthesis CRO (CCRO), small molecule drug chemical synthesis CDMO (CCDMO), and drug molecule building blocks. The one-stop service platform for small molecule new drug research and development chemistry synthesis created by Luhe Ningyuan and its operating model align with the overall development trend of the pharmaceutical industry, empowering global small molecule innovative drug research and development enterprises to shorten R&D time, reduce R&D costs, increase R&D efficiency, and ultimately achieve drug market launch sooner. At the same time, under this model, the company can intervene in the early stages of the customer's product lifecycle, helping the company continuously enhance customer stickiness and form deep cooperative relationships with customers. The company has established long-term stable cooperative relationships with many internationally renowned pharmaceutical companies and domestic and foreign innovative drug companies. International pharmaceutical clients with recognized reputation and influence include Novartis, Roche, Gilead, Johnson & Johnson, Takeda Pharmaceutical, Merck, Bayer, etc.; foreign innovative drug company clients include Enanta, ORIC, DiCE, Fudai Pharmaceuticals, Incyte, Ventyx, Qurient, etc.; the company also actively supports domestic innovative drug companies' drug research and development efforts, aiming to contribute to the development of China's biopharmaceutical industry. Domestic innovative drug company clients include Cniov, Jaccos, Dezhu Pharmaceutical, Tensun Biopharmaceutical, Jiyu Pharmaceutical, Heyu Biological, BEIGENE, Betta Pharmaceuticals, etc. Financially, in the fiscal year 2020, 2021, 2022, and January to June 2023, Luhe Ningyuan achieved operating revenues of approximately RMB 274 million, 421 million, 493 million, and 314 million respectively; during the same periods, the company achieved net profits of 34.49 million, 76.89 million, 87.79 million, and 55.62 million RMB respectively.